Apricus Biosciences Receives European Approval for Vitaros(R) for the Treatment of Erectile Dysfunction

Apricus Biosciences Receives European Approval for Vitaros(R) for the
Treatment of Erectile Dysfunction

Company to Host Conference Call Today at 9:00 AM ET

SAN DIEGO, June 10, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com),
today announced that its marketing application for Vitaros^®, indicated for
the treatment of patients with erectile dysfunction ("ED"), has been approved
through the European Decentralized Procedure ("DCP").

"The approval of Vitaros^® in Europe marks a significant milestone for Apricus
Bio as we continue to execute on our core strategy of developing, seeking
regulatory approval, and partnering our sexual health products," said Richard
Pascoe, Chief Executive Officer of Apricus Bio. "Vitaros^® has a unique
product profile that meets the needs of a large number of patients suffering
from erectile dysfunction and who are intolerant to or do not respond to
current treatment options. With its rapid onset of action and unique topical
delivery, we believe that Vitaros^® will capture a significant share of the
approximately $1 billion PDE-5 inhibitor market in Europe once it is launched
by our commercial partners."

"Moreover, partnering interest in Vitaros^® remains strong and we are actively
seeking to secure additional partnerships in the remaining European and global
markets," continued Pascoe. "With the completion of a $17.1 million financing,
the divestiture of multiple non-core assets, and streamlining of our global
operations in the second quarter of 2013, Apricus Bio is now well positioned
to advance our lead assets for male and female sexual health, Vitaros^® and
Femprox^®, in an effort to create long-term shareholder value."

Under the DCP, Apricus Bio filed its application for marketing approval
designating Netherlands as the Reference Member State ("RMS") on behalf of
nine other European Concerned Member States ("CMS") participating in the
procedure. The CMS include France, Germany, Italy, UK, Ireland, Spain, Sweden,
Belgium and Luxembourg. The Company will continue to work independently as
well as with its commercialization partners, Sandoz, Takeda, and Bracco for
the next step of obtaining national phase approvals in order to make Vitaros^®
ready to launch in each of the included territories across Europe.

Conference Call Information

The call will take place today, June 10 at 9:00 AM ET and can be accessed in
the U.S. by dialing 877-407-9210 and outside of the U.S. by dialing
201-689-8049 and asking the conference operator for the Apricus Bio Conference
Call.The conference call will also be webcast live at
www.investorcalendar.com/IC/CEPage.asp?ID=171060.The teleconference replay
will be available for three months by dialing in the U.S. 877-660-6853 and
outside of the U.S. by dialing 201-612-7415.Replay Passcode 415699 is
required for playback.The webcast replay will be available for three months.

About Vitaros^®

Vitaros^® is a topically-applied cream formulation of alprostadil, a
vasodilator, combined with our proprietary permeation enhancer DDAIP.HCL,
which directly increases blood flow to the penis, causing an erection.
Alprostadil is a widely accepted alternative to the PDE-5 inhibitors for
difficult to treat patients, and Vitaros^®, which was determined to be safe
and effective by the European Health Authorities and previously by Health
Canada, offers greater market opportunity due to its patient-friendly form
versus other alprostadil dosage forms and also relative to oral ED products.
With a market affecting nearly 150 million men worldwide and representing
approximately $1 billion in revenue in Europe, Vitaros^® represents a major
market opportunity, particularly as a distinct product that addresses a
significant underserved population.

About Femprox^®

Femprox^® is our product candidate for the treatment of female sexual arousal
disorder (FSAD) which contains a topically-applied cream formulation of
alprostadil, a vasodilator, and our proprietary permeation enhancer DDAIP.HCL.
Seven clinical studies have been successfully completed to date, including
one, 98-subject Phase 2 study in the US and a nearly 400-subject Phase 3 study
in China. To date, no product has been approved in the U.S. to treat FSAD, a
persistent or recurring inability to attain or maintain adequate sexual
excitement, causing personal distress. Estimates of the FSAD market size put
it on par with erectile dysfunction in males, and possibly larger.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health.The Company has one approved product, Vitaros^®, for the treatment of
erectile dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus Bio's marketing partners which include, Abbott
Canada, Takeda Pharmaceuticals International GmbH, Sandoz, and Bracco SpA.
Femprox^®, the Company's product candidate for the treatment of female sexual
arousal disorder, has successfully completed a nearly 400-subject Phase 3
study in China.

For further information on Apricus Bio, visit http://www.apricusbio.com.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this release,
the matters described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact the matters
herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, its ability to further develop its
product Vitaros^® for erectile dysfunction , and product candidate Femprox^®
for Female Sexual Arousal Disorder among others; to have its product and
product candidates receive additional patent protection and be approved by
relevant regulatory authorities in Europe, the United States and Canada and in
other countries; to successfully commercialize such product and product
candidates and other NexACT^® product candidates and drug delivery technology;
to sell its oncology supportive care business or assets to a third party or
parties; to cease funding to its French subsidiariesand to have such
subsidiaries reorganize or liquidate successfully; and to achieve its other
development, commercialization and financial goals. Readers are cautioned not
to place undue reliance on these forward-looking statements as actual results
could differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company's most
recent annual report on Form 10-K, subsequent quarterly reports filed on Form
10-Q and other filings made with the SEC. Copies of these reports are
available from the SEC's website or without charge from the Company.

CONTACT: Apricus Bio Investor Relations:
        
         David Pitts or Lourdes Catala
         Argot Partners
         212-600-1902
         david@argotpartners.com
         lourdes@argotpartners.com

Apricus logo
 
Press spacebar to pause and continue. Press esc to stop.